Synaffix expands Innovent deal; Recipharm co-develops inhalers; VitriVax gets $5M for vaccine tech
07 Dec 2023
License out/inADC
Welcome to Endpoints News’ manufacturing news briefs, where we bring you essential updates on new builds, collaborations, recalls and more.
Lonza-owned Synaffix boosted its licensing deal with Innovent Biologics on Wednesday to make at least one new ADC candidate, building upon the companies’ original deal in June 2021. Innovent will use Synaffix’s ADC manufacturing technology to develop new ADC candidates. Synaffix will receive an upfront payment as well as further milestone payments and royalties for each commercialized ADC.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.